Clinical Study on Modified Yiqi Shengjiang Decoction Combined with Western Medicine for Treatment of Chronic Heart Failure
10.3969/j.issn.1005-5304.2018.02.008
- VernacularTitle:加味益气升降汤辅助西药治疗慢性心力衰竭临床研究
- Author:
Li-Wei GAO
1
;
Hui-Qing YU
;
Yong-Xin LI
;
Ying-Ying CHANG
;
Yu WANG
;
Yun-Hui MENG
Author Information
1. 石家庄市中医院
- Keywords:
chronic heart failure;
LP-PLA2;
BNP
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2018;25(2):35-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of modified Yiqi Shengjiang Decoction for chronic heart failure (CHF) and its effects on BNP and LP-PLA2. Methods Totally 100 cases of patients with CHF were randomly divided into treatment group and control group, with 50 cases in each group. The control group received basic treatment, and the treatment group was treated with modified Yiqi Shengjiang Decoction on the basis of control group, one dosage per day, twice a day, orally, for 4 weeks. The curative effect of heart function grading and curative effect of TCM symptoms of the two groups, the changes of plasma BNP and LP-PLA2 levels were observed. Safety indicators were monitored. Results The total effective rate of cardiac function classification was 88％ (44/50) in the treatment group and 68％ (34/50) in the control group, with the treatment group much better than the control group (P<0.05); the total effective rate of TCM symptom efficacy was 90％ (45/50) in the treatment group and 74％ (37/50) in the control group, with the treatment group much better than the control group (P<0.05). The BNP and LP-PLA2 levels in the treatment group were lower than the control group after treatment, with statistical significance (P<0.05). No adverse reactions were observed in both groups, with no abnormalities in blood, urine, liver and kidney function. Conclusion Modified Yiqi Shengjiang Decoction combined with Western medicine has obvious advantages in the treatment of CHF in improving patients' heart function, and reducing plasma BNP and LP-PLA2 levels.
